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The JNK signaling pathway is implicated in the regulation of the
AP1 transcription factor and cell proliferation. Here, we examine
the role of JNK by using conditional and chemical genetic alleles of
the ubiquitously expressed murine genes that encode the isoforms
JNK1 and JNK2. Our analysis demonstrates that JNK is not essential
for proliferation. However, JNK is required for expression of the
cJun and JunD components of the AP1 transcription factor, and
JNK-deficient cells exhibit early p53-dependent senescence. These
data demonstrate that JNK can act as a negative regulator of the
p53 tumor suppressor.
AP1  cJun  cell cycle
I t is established that the JNK signaling pathway is a criticalregulator of AP1-dependent gene expression (1). JNK phos-
phorylation of a number of AP1 and AP1-related transcription
factors (e.g., cJun, JunB, JunD, and ATF2) causes increased AP1
transcription activity. In addition, JNK can regulate AP1 activity
by increasing the expression of cJun mRNA (by acting at
AP1-like sites in the cJun promoter) and regulating the half-life
of the cJun protein (1). This role of JNK to increase AP1-
dependent gene expression suggests that JNK may play an
important role in cellular responses to mitogens (2). Indeed,
primary murine fibroblasts (MEF) isolated from compound
mutant Jnk1/ Jnk2/ embryos proliferate slowly (3).
The observation that MEF that lack JNK expression grow
slowly suggests that JNK may function to regulate cell-cycle
progression. However, the target of JNK signaling that mediates
this effect of JNK on proliferation has not been defined. In
addition, it is unclear whether the requirement of JNK for
proliferation reflects a role for JNK-mediated phosphorylation
of a substrate that is critically required for cell-cycle progression
or whether it is the prolonged absence of JNK that causes slow
growth.
To test whether JNK is required for proliferation, we exam-
ined the effect of acute loss of JNK function on cellular
proliferation. A drug with validated specificity for JNK is not yet
available (4). We therefore used genetic approaches to examine
the effect of acute loss of JNK function on proliferation.
Results and Discussion
Construction of a Conditional Jnk1 Allele. Mice with a floxed allele
of Jnk1 were constructed by using standard techniques (Fig. 1
A–C). These mice were crossed with JNK2-deficient mice to
create Jnk1LoxP/LoxP Jnk2/ mice. Primary MEF prepared from
these animals expressed JNK1. Alternative splicing of Jnk1
mRNA results in the expression of 46-kDa isoforms of JNK1
with a small amount of 54-kDa JNK1 isoforms (5). Cre-mediated
excision of the floxed Jnk1 alleles resulted in primary MEF that
lack detectable JNK expression (Fig. 1D). We have previously
reported that JNK-deficient primary MEF display reduced
UV-stimulated apoptosis and increased TNF-stimulated apo-
ptosis (3, 6). The compound knockout MEF derived from
conditional JNK mice similarly exhibited reduced UV-
stimulated apoptosis and increased TNF-stimulated apoptosis
[supporting information (SI) Figs. 7 and 8]. These data indicate
that primary MEF isolated from conditional JNK-deficient mice
are suitable for the analysis of the acute effects of compound
JNK deficiency.
PCR analysis of genomic DNA demonstrated that the Cre-
mediated deletion of floxed Jnk1 alleles was rapid. However,
immunoblot analysis indicated that JNK1 expression slowly
decreased after Jnk1 gene ablation (Fig. 2A). Indeed, low levels
of JNK1 protein were detected at 3 days after Cre-mediated
deletion. This slow loss of JNK1 protein expression is consistent
with the half-life of the JNK1 protein (8 h) (1). Nevertheless,
MEF without JNK (Jnk-null MEF) were obtained within 6 days
after exposure to Cre-recombinase (Fig. 2A).
JNK Deficiency Causes a Delayed Decrease in Proliferation. We have
previously reported that MEF isolated from Jnk1/ Jnk2/
embryos grow slowly (3). In contrast, f low cytometry analysis of
BrdU incorporation into DNA demonstrated that JNK defi-
ciency caused no decrease in DNA synthesis at passage 3 (9 days)
after Cre-mediated abation of JNK expression (Fig. 2B). This
observation indicates that there is no essential requirement of
JNK for proliferation. The slow growth of MEF isolated from
Jnk1/ Jnk2/ embryos (3) contrasts with the rapid prolifer-
ation of Jnk-null MEF created by using Cre-recombinase. One
possible explanation for the different phenotypes of these MEF
is that slow growth is a delayed consequence of JNK deficiency.
To test this hypothesis, we passagedMEF by using a 3T3 protocol
(Fig. 2 C and D). Studies of Jnk-null MEF demonstrated a
progressive decrease in growth with increasing passage number.
Indeed, at passage 7 (21 days after Cre-mediated JNK ablation)
the Jnk-null MEF exhibited a flattened morphology (Fig. 2C)
and proliferated very slowly (Fig. 2D). Together, these data
indicate that JNK is not essential for proliferation, but long-term
JNK deficiency causes a severe decrease in proliferation.
The mechanism that accounts for the delayed requirement of
JNK for proliferation is unclear. One possible explanation is that
JNK deficiency causes changes in gene expression. It is estab-
lished that JNK is a critical regulator of the AP1 transcription
factor (1) and that AP1 is important for proliferation (2).
Decreased AP1 in Jnk-nullMEFmay therefore contribute to the
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observed reduction in proliferation. To test whether Jnk-null
MEF expressed lower levels of AP1 proteins, we examined the
expression of cJun, JunB, JunD, and cFos mRNA. Analysis of
Jnk-nullMEFdemonstrated a selective loss of JunDmRNA (Fig.
3A). It is established that JNK can stabilize the cJun protein (7,
8). Thus, although Jnk-null MEF did not exhibit a decrease in
cJun mRNA, reduced expression of cJun protein was antici-
pated. Indeed, immunoblot analysis demonstrated that the
amount of cJun protein was markedly reduced in Jnk-nullMEF.
Together, these data indicate that Jnk-null MEF express de-
creased amounts of both cJun and JunD (Fig. 3). Interestingly,
both cJun/ MEF and JunD/ MEF exhibit profoundly
reduced proliferation (9, 10). Thus, reduced expression of cJun
and JunD may contribute to the reduced proliferation of Jnk-
null MEF.
JNK Deficiency Causes Senescence. The delayed defect in the
growth of Jnk-nullMEF suggests that JNK deficiency may cause
senescence. To test this hypothesis, we stained MEF for acidic
-gal, a biochemical marker of senescence (11). This analysis
confirmed that the Jnk-null MEF exhibited a progressive in-
crease in senescence when passaged with a 3T3 protocol (Fig. 4
A and B) with a flattened morphology that is characteristic of
senescent cells (Fig. 4C). These data indicate that JNK defi-
ciency causes senescence.
JNK is required to prevent premature senescence (Fig. 4).
However, it is unclear whether this reflects a requirement for the
kinase activity of JNK, because kinase-independent actions of
JNK have been reported (12). To test whether the protein kinase
activity of JNK is required to prevent early senescence, we used
a chemical genetic approach to inhibit JNK activity with the drug
1-naphthylmethyl-4-amino-1-tert-butyl-3-(p-methylphenyl)-
pyrazolo[3,4-d]pyrimidine (1NM-PP1) (13). This drug does not
inhibit the activity of WT JNK, but does inhibit the activity of a
mutant form of JNK (Met-108 replaced with Gly) that has an
expanded ATP pocket (14). Mice with this point mutation in the
Jnk2 gene (Jnk2MG) have been described (13). We prepared
MEF from WT embryos and Jnk1/ Jnk2MG/MG embryos.
Treatment of WT MEF with the drug 1NM-PP1 during a 3T3
protocol caused no marked changes in proliferation (Fig. 5A). In
contrast, treatment of Jnk1/ Jnk2MG/MG MEF with 1NM-PP1
caused severely reduced growth in a 3T3 protocol (Fig. 5A),
increased expression of the senescence marker acidic -gal (Fig.
5B), and a senescent morphology (Fig. 5C). Together, these data
indicate that JNK activity is required to prevent early senescence.
JNK Deficiency Increases p53 Expression and Activity.MEF prepared
from Jnk1/ Jnk2/ embryos express increased amounts of the
Mdm2 inhibitor p19ARF and increased amounts of p53 protein
(3). The increased expression of p53 is most likely caused by both
increased p53 protein stability, as a result of increased p19ARF
expression (15), and an increase in p53 mRNA expression (Fig.
6A) caused by reduced cJun expression and derepression of the
p53 promoter (16). To test whether the increased expression
of p53 in Jnk-null MEF is functionally significant, we examined
p53-dependent gene expression. These studies demonstrated
that Jnk-null MEF exhibited increased expression of the p53
target genes Mdm2 and p21 (Fig. 6A). These data demonstrate
that there is an increase in p53 expression and function in
Jnk-null MEF.
JNK Deficiency Causes p53-Dependent Senescence. The p53 tumor
suppressor is implicated in senescence. The increased expression
and function of p53 in Jnk-nullMEFmay therefore contribute to
the early senescent phenotype of these cells. To test this hypoth-
esis, we examined the effect of p53 down-regulation by using the
human papilloma virus (HPV)-16 E6 protein. The expression of
E6 in WT MEF caused no major change in the proliferation of
WT MEF in a 3T3 protocol. In contrast, expression of E6 in
Jnk-null MEF prevented the early senescent phenotype of these
cells (Fig. 6 B andC). Thus, E6-mediated down-regulation of p53
prevents senescence caused by JNK deficiency. Together, these
data indicate that JNK is not required for proliferation, but JNK
does function to prevent p53-mediated senescence.
Fig. 1. Construction of a conditional Jnk1allele in mice. (A) The strategy used
for targeting the Jnk1gene to create a conditional Jnk1LoxP allele is illustrated.
A probe used for Southern blot analysis and the expected BamH1 restriction
fragments are shown. (B) Southern blot analysis of BamH1-restricted genomic
DNA isolated from WT and Jnk1/LoxP ES cells is shown. (C) Genomic DNA was
isolated from the tails of WT and Jnk1/LoxPmice and examined by PCR analysis.
(D) Primary MEF were isolated from WT mice and Jnk1LoxP/LoxP Jnk2/ mice.
The MEF were transduced by using a retroviral Cre expression vector. The MEF
were cultured (7 days) and extracts were examined by immunoblot analysis
using antibodies to JNK1/2 and ERK1/2.
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Role of JNK in Cell Proliferation and Senescence.The conclusion that
JNK is not required for proliferation markedly contrasts with
conclusions drawn from previous studies (3). Acute loss of JNK
function does not inhibit proliferation (Fig. 2B). However, JNK
deficiency does cause p53-dependent senescence (Fig. 4). The
slow proliferation of JNK-deficient MEF isolated from Jnk1/
Jnk2/ embryos that was reported previously (3) is most likely
a consequence of chronic JNK deficiency and p53-dependent
senescence rather than a direct role for JNK in the cell cycle.
Interestingly, the effect of JNK deficiency to cause early p53-
dependent senescence is similar to that caused by deficiency of
the AP1 proteins cJun (10, 16) and JunD (9). The large decrease
in cJun and JunD expression caused by JNK deficiency (Fig. 3)
may therefore contribute to the engagement of the p53 senes-
cence pathway in Jnk-null MEF. Indeed, ectopic expression of
JunD in Jnk-nullMEF partially suppressed p53-mediated senes-
cence (SI Fig. 9).
The progressive decrease in AP1 protein expression after loss
of JNK over several days (Figs. 2A and 3B) may explain the
finding that loss of JNK does not immediately inhibit prolifer-
ation (Fig. 2B), but p53-induced senescence is observed later
(Fig. 4). Collectively, these data indicate that JNK can act as a
negative regulator of the p53 tumor suppressor. This conclusion
is consistent with recent reports that have implicated a role for
the JNK signaling pathway in some human tumors (17).
Materials and Methods
Animal Studies. Mice with disruptions of the Jnk1 or Jnk2 genes
or a knock-in mutation in the Jnk2 gene (Jnk2MG) have been
described (13, 18, 19). Mice expressing a 4-hydroxytamoxifen-
inducible Cre recombinase from the endogenous
Gt(ROSA)26Sor promoter (20) were obtained from the Jackson
Laboratory (Bar Harbor, ME). Mice with a germ-line mutation
in the Jnk1 gene with LoxP elements inserted into two different
introns (Jnk1LoxP) were constructed by using homologous re-
combination in ES cells. A mouse strain 129/Svev genomic BAC
clone containing the Jnk1 gene was used to create a targeting
vector with a floxed NeoR cassette and a thymidine kinase
cassette (Fig. 1A). ES cells were electroporated with this vector
and selected with 200 g/ml G418 and 2 M gangcyclovir. Two
correctly targeted ES cell clones were identified by Southern blot
analysis and PCR analysis. These ES cell clones were injected
into C57BL/6J blastocysts to create chimeric mice that trans-
mitted the mutated Jnk1 allele through the germ line. The floxed
NeoR cassette was excised by using Cre recombinase. The mice
were backcrossed to the C57BL/6J strain (Jackson Laboratory)
and housed in a facility accredited by the American Association
for Laboratory Animal Care. These studies were approved by the
Institutional Animal Care and Use Committee of the University
of Massachusetts Medical School.
Genotype Analysis. The genotype at the Jnk1 locus was examined
by Southern blot analysis of BamHI-restricted genomic DNA by
probing with a random-primed 32P-labeled probe (320 bp) that
was isolated by PCR using a Jnk1 genomic clone as the template
and the primers 5-GGTACTGTGTCAGCCTGGTCAAG-3
and 5-GGGGGAACCAAACCAAAAAAC-3. The WT and
conditional alleles of Jnk1 were also detected by PCR amplifi-
cation of genomic DNA using the primers 5-GGATTTATGC-
CCTCTGCTTGTC-3 and 5-GAACCACTGTTCCAATTTC-
CATCC-3; agarose gel electrophoresis indicates the presence of
a 520-bp DNA fragment (WT Jnk1 allele) or a 330-bp DNA
Fig. 2. JNK deficiency causes a delayed reduction in cellular proliferation. (A) Time-course analysis of JNK expression after gene ablation. Jnk1LoxP/LoxP Jnk2/
MEF were transduced by using a retroviral Cre expression vector. Cell extracts were prepared on different days after infection and examined by immunoblot
analysis using antibodies to JNK, cJun, and ERK. Extracts prepared from WT MEF were also examined. (B) The effect of retroviral tranduction of Cre in WT and
Jnk1LoxP/LoxP Jnk2/ MEF was examined 10 days after infection by measurement of the incorporation of BrdU by flow cytometry. (C) The morphology of WT
and Jnk1LoxP/LoxP Jnk2/MEF at passage 7 after retroviral transduction ofCrewas examined by phase-contrast microscopy. (Magnification:100.) (D) The growth
of WT and Jnk1LoxP/LoxP Jnk2/ MEF was examined by using a 3T3 assay. The data are presented as the accumulated population doublings during eight passages
in culture. The effect of retroviral transduction of Cre was investigated.








fragment ( floxed Jnk1 allele). The deleted Jnk1 allele (Jnk1)
was detected by PCR amplification of genomic DNA using the
primers 5-CCTCAGGAAGAAAGGGCTTATTTC-3 and 5-
GAACCACTGTTCCAATTTCCATCC-3; agarose gel elec-
trophoresis indicates the presence of a 1,550-bp fragment (WT
Jnk1 allele), a 1,095-bp DNA fragment ( floxed Jnk1 allele), or a
395-bp DNA fragment (Jnk1 allele).
Primary Cell Culture.MEF were isolated from E13.5 embryos and
cultured in DMEM supplemented with 10% heat-inactivated
FBS, 2 mM glutamine, 100 units/ml of penicillin, and 100 g/ml
of streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a humid-
ified atmosphere with 5% CO2. Similar data were obtained in
experiments using independently isolated MEF cultures. The
cells were treated without or with the drug 1NM-PP1 (13).
Retroviral transduction experiments were performed with a
self-inactivating vector (HR-MMPCreGFP) that transiently ex-
presses Cre recombinase (21), a vector (pLXSN16E6) that
expresses HPV-16 E6 (22), and a vector (pMSCV-JunD-IRES-
GFP) that expresses JunD (6). MEF proliferation was monitored
with a 3T3 protocol (23). Proliferation assays were performed by
staining with crystal violet (3), measurement of cell number with
a hemacytometer, and measurement of BrdU incorporation by
flow cytometry (24). Senescent cells were detected by staining
for -gal using X-Gal (Cell Signaling, Danvers, MA).
Fluorescence Microscopy. MEF were fixed with 2% formaldehyde
(15 min), permeabilized with 0.1% Triton X-100/PBS (5 min),
stained with Alexa Fluor 488-conjugated phalloidin (Invitrogen)
Fig. 3. JNK deficiency causes reduced expression of cJun and JunD. (A) WT
and Jnk1LoxP/LoxP Jnk2/ MEF were transduced by using a Cre retroviral
expression vector. RNA was isolated from these cells at passage 7 postinfection
and examined by quantitative RT-PCR (Taqman) analysis using probes for AP-1
transcription factors (cJun, JunB, JunD, and cFos) and GAPDH. The data are
presented as the normalized ratio of [AP-1 mRNA]/[GAPDH mRNA]. (B) Protein
extracts were prepared from MEF at 3T3 passages 3, 5, and 7 postinfection and
examined by immunoblot analysis using antibodies to cJun, JNK, and ERK.
Fig. 4. JNK deficiency causes senescence. (A) WT and Jnk1LoxP/LoxP Jnk2/
MEF were transduced by using a Cre retroviral expression vector and stained
for a senescence marker (acidic -gal) using X-Gal. A culture stained at 3T3
passage 9 postinfection is illustrated. (B) The percentage of cells that stained
with X-Gal was examined at passages 5, 6, 7, 8, and 9 postinfection was
quantitated. The data shown represent the mean SD of three independent
experiments. (C) MEF at 3T3 passage 9 postinfection were stained with phal-
loidin (green) and examined by fluorescence microscopy. (Magnification:
100.)
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diluted 1:1,000 in PBS (15 min), and washed three times
with PBS. The stained MEF were examined by fluorescence
microscopy.
Biochemical Analysis. Gene expression was examined by mea-
surement of the amount of mRNA using quantitative RT–PCR
analysis with Taqman probes (Applied Biosystems, Foster City,
CA). Apoptotic cell death was examined by measurement of
DNA fragmentation using the Cell Death Detection Elisaplus
kit (Roche, Indianapolis, IN) following the manufacturer’s
recommendations (6, 25). Immunoblot analysis was performed
by probing with antibodies to JNK1/2 (Pharmingen, Franklin
Lakes, NJ), cJun (Santa Cruz Biotechnology, Santa Cruz, CA),
JunD (Santa Cruz Biotechnology), and ERK1/2 (Cell
Signaling).
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Fig. 5. Inhibition of the protein kinase activity of JNK causes senescence. (A)
The growth of WT and Jnk1/ Jnk2MG/MG MEF was examined by using a 3T3
assay. The data are presented as the accumulated population doublings
during six passages in culture. The effect of addition of solvent (DMSO) or drug
(1 M 1NM-PP1) was investigated. (B) WT and Jnk1/ Jnk2MG/MG MEF were
stained for a senescence marker (acidic -gal) by using X-Gal. The percentage
of cells that stained with X-Gal was examined at 3T3 passages 5, 6, and 7 and
quantitated. The data shown represent the mean SD of three independent
experiments. (C) MEF at 3T3 passage 7 were stained with phalloidin (green)
and examined by fluorescence microscopy. (Magnification: 100.)
Fig. 6. JNK deficiency causes p53-dependent senescence. (A) WT and
Jnk1LoxP/LoxP Jnk2/ MEF were transduced by using a Cre retroviral expres-
sion vector. Total RNA was isolated from MEF at 3T3 passage 7 postinfec-
tion and the amount of p53, Mdm2, p21, p16, and GAPDH mRNA was
measured by quantitative RT-PCR (Taqman assays). The data are presented
as the normalized ratio of [p53, Mdm2, p21, or p16 mRNA]/[GAPDH mRNA].
(B) The growth of WT and Jnk1LoxP/LoxP Jnk2/ MEF (transduced with a
retroviral Cre vector) was examined by using a 3T3 assay. The effect of
expression of the HPV16 E6 protein is presented. The data are presented as
the accumulated population doublings during 10 passages in culture
postinfection. (C) WT and Jnk1LoxP/LoxP Jnk2/ MEF (transduced with a
retroviral Cre vector) were stained for a senescence marker (acidic -gal) by
using X-Gal. The effect of expression of the HPV16 E6 protein is presented.
The percentage of cells that stained with X-Gal was examined at 3T3
passage 7 postinfection and quantitated. The data shown represent the
mean  SD of three independent experiments.
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